This is exemplified by the observation that whereas mutational loss of EZH2 promotes the development of myelodysplastic syndrome (MDS), it attenuates MDS progression to acute myeloid leukemia by suppressing expression of the leukemic oncogene Hoxa9 [144]. This evidence concerns the gene HOXA9 and myelodysplastic syndrome.